Analysis of the Clinical Efficacy of Dendritic Cell –cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer

Xu, Huiru; Qin, Weishan; Feng, Huijing; Dong, Song; Yang, Xiaoling; Zhang, Junping

doi:10.1080/08820139.2020.1781881

Cited by 8 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through patients in all study arms receiving CIK therapy; and patients in the control arm being healthy subjects. Thus, 70 studies containing 16 English 17,19,[25][26][27][28][29][30][31][32][33][34][35][36][37][38] and 44 Chinese 24,39-91 language articles were selected for study synthesis (Figure 1).…”

Section: Search Resultsmentioning

confidence: 99%

“…In 25 studies 17,25,27,28,[31][32][33][34][35][36][37]40,41,46,47,[49][50][51]56,58,65,71,75,77,87 , patients in the intervention arm received CIK therapy, while in 45 studies 19,24,26,29,30,38,39,[42][43][44][45]48,[52][53][54][55]57,[59][60][61][62][63][64][66][67][68][69]…”

Section: Interventionsmentioning

confidence: 99%

“…Chemotherapy was the most common co-treatment with CIK or DC-CIK therapy, being utilised in 66 studies 17,19,[24][25][26][82][83][84][85][86][87][88][89][90] . The most commonly utilised chemotherapy regimens were FOLFOX and XELOX, being administered in 43 17,24,28,29,31,32,[34][35][36][37]39,41,43,45,48,50,51,55,[57][58][59][60][61][62][63][64][65][66][69][70][71][73][74][75][76]78,79,…”

Section: Interventionsmentioning

confidence: 99%

“…Imbalance in age, cancer stage and history of primary cancer resection was noted for 3 studies 17,37,38 and they were similarly assessed to be at unclear risk of selection bias. Unclear risk of performance bias due to uncertainty around uniformity of non-CIK/DC-CIK treatment across the intervention and control arms was identified in 21 studies 26,29,31,33,34,38,43,44,48,52,53,55,58,62,76,[79][80][81]83,84,88 with all the studies except one failing to adequately describe study interventions or the proportion of patients receiving various interventions. In the remaining 1 study 81 , patients in the intervention arm received DC-CIK therapy alone, while those in the control arm received best supportive care.…”

Section: Risk Of Bias Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis

Tomita

Dhakal

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) are increasing. In many of these trials CIK therapy was co-administered with conventional cancer therapy. The aim of this review is to systematically assess the available literature, in which the majority were only in Chinese, on CIK therapy for the management of CRC using meta-analysis, and to identify parameters associated with successful CIK therapy implementation. Methods: Prospective and retrospective clinical studies which compared CIK therapy to non-CIK therapy in CRC patients were searched for electronically on MEDLINE, Embase, CNKI and Wanfang Data databases. The clinical endpoints of overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall response rate (ORR) and toxicity were meta-analysed using hazard (HR) and relative ratios (RR), and subgroup analyses were performed using Chi-square (Chi2) test and I-square (I2) statistics for study design, disease stage, co-therapy type, and timing of administration. Results: In total, 70 studies involving 6,743 patients were analysed. CIK therapy was favoured over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53-0.65), PFS (HR=0.55, 95% CI: 0.47-0.63), and ORR (RR=0.65, 95% CI: 0.57-0.74) without increasing toxicity (HR=0.59, 95% CI 0.16-2.25). Subgroup analyses on OS and PFS by study design (randomised versus non-randomised study design), disease stage (Stage I-III versus Stage IV), co-treatment with dendritic cells (CIK versus DC-CIK therapy), or timing of therapy administration (concurrent versus sequential with co-administered anti-cancer therapy) also showed that the clinical benefit of CIK therapy was robust in any subgroup analysis. Furthermore, co-treatment with dendritic cells did not improve clinical outcomes over CIK therapy alone. Conclusions: Compared with standard therapy, patients who received additional CIK cell therapy had favourable outcomes without increased toxicity, warranting further investigation into CIK therapy for the treatment of CRC.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Interventionsmentioning

confidence: 99%

Section: Interventionsmentioning

confidence: 99%

Section: Risk Of Bias Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis

Tomita

Dhakal

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…DC-CIK combined with capecitabine prolonged PFS in the treatment of patients with recurrent and metastatic triple-negative breast cancer ( 169 ). In addition, DC-CIK combined with adjuvant chemotherapy can significantly prolong the DFS of patients with postoperative colorectal cancer ( 170 ). In the treatment of GC, a meta-analysis showed that DC-CIK combined with chemotherapy can significantly improve the OS rate, DFS rate, and T lymphocyte reaction in patients after GC surgery ( 171 ).…”

Section: Dcs-based Immunotherapymentioning

confidence: 99%

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

et al. 2022

View full text Add to dashboard Cite

Gastric cancer (GC) is a malignancy with a high incidence and mortality, and the emergence of immunotherapy has brought survival benefits to GC patients. Compared with traditional therapy, immunotherapy has the advantages of durable response, long-term survival benefits, and lower toxicity. Therefore, targeted immune cells are the most promising therapeutic strategy in the field of oncology. In this review, we introduce the role and significance of each immune cell in the tumor microenvironment of GC and summarize the current landscape of immunotherapy in GC, which includes immune checkpoint inhibitors, adoptive cell therapy (ACT), dendritic cell (DC) vaccines, reduction of M2 tumor-associated macrophages (M2 TAMs), N2 tumor-associated neutrophils (N2 TANs), myeloid-derived suppressor cells (MDSCs), effector regulatory T cells (eTregs), and regulatory B cells (Bregs) in the tumor microenvironment and reprogram TAMs and TANs into tumor killer cells. The most widely used immunotherapy strategies are the immune checkpoint inhibitor programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T lymphocyte–associated protein 4 (CTLA-4) antibody, and chimeric antigen receptor T (CAR-T) in ACT, and these therapeutic strategies have significant anti-tumor efficacy in solid tumors and hematological tumors. Targeting other immune cells provides a new direction for the immunotherapy of GC despite the relatively weak clinical data, which have been confirmed to restore or enhance anti-tumor immune function in preclinical studies and some treatment strategies have entered the clinical trial stage, and it is expected that more and more effective immune cell–based therapeutic methods will be developed and applied.

show abstract

Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges

Ying Li,

Li,

Drew

et al. 2024

Cancer Treatment Reviews

View full text Add to dashboard Cite

Analysis of the Clinical Efficacy of Dendritic Cell –cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer

Cited by 8 publications

References 15 publications

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges

Contact Info

Product

Resources

About